Cialis Or Viagra Switch? Sanofi Survey, Pfizer Help Wanted Ad Could Be Signs
This article was originally published in The Pink Sheet
Executive Summary
Viagra marketer Pfizer also could have nonprescription sales in sight as it recruits a "global sexual health" brand manager with responsibilities including shepherding market expansion through an Rx-to-OTC switch.
You may also be interested in...
US FDA's ACNU Proposed Rule Played Petros Pharma’s Tune To Attempt OTC Switch Of ED Drug
For ED products, “where you have a contraindication for current use of nitrates, this enables you now to leverage technology to help assist the consumer without a physician intermediary to appropriately self-select. Yes, music to our ears, we loved it,” says president Fady Boctor.
‘Critical Step’ For Petros Toward ED Switch Proposal With OTC Label Comprehension Study
Firm reports “significant comprehension” among 480 participants. It also expects DFL technology it’s developing for potential OTC sales of Stendra ED drug could be used for other OTC switch proposals.
Sanofi Counts On OTC Switches Adding $1bn In Consumer Revenues By 2026
Sanofi eyes $1bn top line growth from OTC switches of ED drug Cialis and flu drug Tamiflu after they launch by 2026, says CEO Paul Hudson. Like switch consultants, though, he acknowledges the high bar for approval moving additional Rx ingredients to OTC.